SOLUTION STRUCTURE OF HUMAN THIOREDOXIN IN A MIXED DISULFIDE INTERMEDIATE COMPLEX WITH ITS TARGET PEPTIDE FROM THE TRANSCRIPTION FACTOR NF-KAPPA-B

被引:207
作者
QIN, J [1 ]
CLORE, GM [1 ]
KENNEDY, WM [1 ]
HUTH, JR [1 ]
GRONENBORN, AM [1 ]
机构
[1] NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892
基金
美国国家卫生研究院;
关键词
DISULFIDE-BONDED INTERMEDIATE; HUMAN THIOREDOXIN; TRANSCRIPTION FACTOR NF-KAPPA-B;
D O I
10.1016/S0969-2126(01)00159-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Human thioredoxin is a 12 kDa cellular redox protein that plays a key role in maintaining the redox environment of the cell. It has recently been shown to be responsible for activating the DNA-binding properties of the cellular transcription factor, NF kappa B, by reducing a disulfide bond involving Cys62 of the p50 subunit. Using multidimensional heteronuclear-edited and heteronuclear-filtered NMR spectroscopy, we have solved the solution structure of a complex of human thioredoxin and a 13-residue peptide extending from residues 56-68 of p50, representing a kinetically stable mixed disulfide intermediate along the reaction pathway. Results: The NF kappa B peptide is located in a long boot-shaped cleft on the surface of human thioredoxin delineated by the active-site loop, helices alpha 2, alpha 3 and alpha 4, and strands beta 3 and beta 4. The peptide adopts a crescent-like conformation with a smooth 110 degrees bend centered around residue 60 which permits it to follow the path of the cleft. Conclusions: In addition to the intermolecular disulfide bridge between Cys32 of human thioredoxin and Cys62 of the peptide, the complex is stabilized by numerous hydrogen-bonding, electrostatic and hydrophobic interactions which involve residues 57-65 of the NF kappa B peptide and confer substrate specificity. These structural features permit one to suggest the specificity requirements for human thioredoxin-catalyzed disulfide bond reduction of proteins.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 85 条
[1]   REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO [J].
ABATE, C ;
PATEL, L ;
RAUSCHER, FJ ;
CURRAN, T .
SCIENCE, 1990, 249 (4973) :1157-1161
[2]  
BANNISTER AJ, 1991, ONCOGENE, V6, P1243
[3]  
BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63
[4]  
BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141
[5]   METHODOLOGICAL ADVANCES IN PROTEIN NMR [J].
BAX, A ;
GRZESIEK, S .
ACCOUNTS OF CHEMICAL RESEARCH, 1993, 26 (04) :131-138
[6]   ISOTOPE-FILTERED 2D HOHAHA SPECTROSCOPY OF A PEPTIDE-PROTEIN COMPLEX USING HETERONUCLEAR HARTMANN-HAHN DEPHASING [J].
BAX, A ;
GRZESIEK, S ;
GRONENBORN, AM ;
CLORE, GM .
JOURNAL OF MAGNETIC RESONANCE SERIES A, 1994, 106 (02) :269-273
[7]  
BAX A, 1994, METHOD ENZYMOL, V239, P79
[8]   ENZYMATIC REDUCTION OF DISULFIDE BONDS IN FIBRIN-OGEN BY THIOREDOXIN SYSTEM .1. IDENTIFICATION OF REDUCED BONDS AND STUDIES ON REOXIDATION PROCESS [J].
BLOMBACK, B ;
BLOMBACK, M ;
FINKBEINER, W ;
HOLMGREN, A ;
KOWALSKA.B ;
OLOVSON, G .
THROMBOSIS RESEARCH, 1974, 4 (01) :55-75
[9]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[10]  
Brunger A. T., X PLOR VERSION 3 1 S